TY - JOUR T1 - Efficacy of Multimodality Approach in Patients With Recurrent Head and Neck Squamous Cell Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 1255 LP - 1263 DO - 10.21873/anticanres.16272 VL - 43 IS - 3 AU - PASCALE ALICIA HOELL AU - KHALED ELSAYAD AU - HENDRIK BERSSENBRUEGGE AU - DOMINIK HERING AU - CHRISTOPHER KITTEL AU - JOHANNES KLEINHEINZ AU - ANNALEN BLECKMANN AU - GEORG EVERS AU - EVA WARDELMANN AU - CLAUDIA RUDACK AU - HANS THEODOR EICH Y1 - 2023/03/01 UR - http://ar.iiarjournals.org/content/43/3/1255.abstract N2 - Background/Aim: Head and neck squamous cell carcinoma (HNSCC) is characterized by high relapse rates and low survival in comparison to other malignancies. Patients and Methods: Fifty-two patients suffering from recurrent HNSCC were compared, analyzing the impact of different regimes, including surgery, radiotherapy (RT), chemotherapy and immunotherapy on progression-free survival (PFS), overall survival (OS), locoregional control (LRC), and adverse events. Results: The standard RT technique was intensity-modulated radiotherapy (IMRT) in all patients. In the multivariate analysis, higher cumulative RT dose significantly influenced LRC whereas surgery and age significantly impacted PFS and OS. Conclusion: IMRT dose-escalation, as well as surgery, appear beneficial in the treatment of recurrent HNSCC. Moreover, nivolumab and platin-based therapy might be superior agents for systemic therapy in comparison to cetuximab. ER -